DMDaniel Medina

Daniel Medina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Medina has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High‐dimensional spectral flow cytometry uncovers progressive T‐cell exhaustion and myeloid cell reprogramming in a CLL mouse model

    by Hannah Briesch, Mariana Coelho, Alessia Floerchinger, Yuliia Borysovych, Nicolas Aubert, Daniel Medina‐Gil, Manina Breitinger, Marc Zapatka, Stella E. Autenrieth, Martina Seiffert

    Chronic lymphocytic leukemia (CLL) exhibits marked clinical heterogeneity that cannot be fully explained by genetic alterations, underscoring the critical role of the tumor microenvironment in disease progression and therapeutic resistance. To delineate the temporal evolution of immune dysregulation in CLL, we used the Eµ‐TCL1 adoptive transfer (TCL1‐AT) mouse model combined with high‐dimensional spectral flow cytometry to longitudinally profile lymphoid and myeloid compartments. To assess the reproducibility across different disease kinetics, we analyzed seven independent TCL1‐AT cohorts generated from distinct primary tumors. CLL progression was associated with coordinated restructuring of adaptive and innate immune cell populations. Within the T‐cell compartment, early activation and effector expansion transitioned to a progressive accumulation of terminally exhausted CD8 + T cells. Concurrently, immunoregulatory populations expanded, including regulatory type 1 (Tr1)‐like CD4 + T cells, activated regulatory T cells (Tregs) and, importantly, a previously underappreciated Eomes‐expressing Treg subset. Natural killer (NK) cells exhibited transient expansion followed by differentiation and acquisition of exhaustion markers. Myeloid cell profiling revealed an expansion of immunosuppressive PD‐L1 high patrolling monocytes, mature regulatory dendritic cells (mregDCs), and phenotypic reprogramming of dendritic cells (DCs) consistent with impaired antigen presentation and promotion of T‐cell exhaustion and regulatory T‐cell subsets. Despite substantial variation in leukemia kinetics, expansion of patrolling monocytes, exhausted CD8 + T cells, and Tregs was consistently observed across all seven independent TCL1‐AT cohorts, demonstrating robust immune remodeling. Collectively, our findings demonstrate a stepwise transition toward a suppressive microenvironment involving innate and adaptive immune compartments in the Eµ‐TCL1 mouse model, providing a framework for understanding immune failure in CLL and informing strategies to restore anti‐leukemic immunity.

  • Open Access

    Related Article from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model

    by Martín C. Abba, Yuhui Hu, Carla C. Levy, Sally Gaddis, Frances S. Kittrell, Jamal Hill, Reid P. Bissonnette, Powel H. Brown, Daniel Medina, C. Marcelo Aldaz

  • Open Access

    Supplementary Materials 1 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model

    by Martín C. Abba, Yuhui Hu, Carla C. Levy, Sally Gaddis, Frances S. Kittrell, Jamal Hill, Reid P. Bissonnette, Powel H. Brown, Daniel Medina, C. Marcelo Aldaz

  • Open Access

    Supplementary Materials 2 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model

    by Martín C. Abba, Yuhui Hu, Carla C. Levy, Sally Gaddis, Frances S. Kittrell, Jamal Hill, Reid P. Bissonnette, Powel H. Brown, Daniel Medina, C. Marcelo Aldaz

  • Open Access

    Supplementary Materials 3 from Identification of Modulated Genes by Three Classes of Chemopreventive Agents at Preneoplastic Stages in a p53-Null Mouse Mammary Tumor Model

    by Martín C. Abba, Yuhui Hu, Carla C. Levy, Sally Gaddis, Frances S. Kittrell, Jamal Hill, Reid P. Bissonnette, Powel H. Brown, Daniel Medina, C. Marcelo Aldaz

  • Open Access

    A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression

    by Pau Abrisqueta, Daniel Medina, Guillermo Villacampa, Junyan Lu, Miguel Alcoceba, Julia Carabia, Joan Boix, Barbara Tazón-Vega, Gloria Iacoboni, Sabela Bobillo, et al.

    Several gene expression profiles with a strong correlation with patient outcomes have been previously described in chronic lymphocytic leukemia (CLL), although their applicability as biomarkers in clinical practice has been particularly limited. Here we describe the training and validation of a gene expression signature for predicting early progression in patients with CLL based on the analysis of 200 genes related to microenvironment signaling on the NanoString platform. In the training cohort (n = 154), the CLL15 assay containing a 15-gene signature was associated with the time to first treatment (TtFT) (hazard ratio [HR], 2.83; 95% CI, 2.17-3.68; P < .001). The prognostic value of the CLL15 score (HR, 1.71; 95% CI, 1.15-2.52; P = .007) was further confirmed in an external independent validation cohort (n = 112). Notably, the CLL15 score improved the prognostic capacity over IGHV mutational status and the International Prognostic Score for asymptomatic early-stage (IPS-E) CLL. In multivariate analysis, the CLL15 score (HR, 1.83; 95% CI, 1.32-2.56; P < .001) and the IPS-E CLL (HR, 2.23; 95% CI, 1.59-3.12; P < .001) were independently associated with TtFT. The newly developed and validated CLL15 assay successfully translated previous gene signatures such as the microenvironment signaling into a new gene expression–based assay with prognostic implications in CLL.


  • Open Access

    Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

    by Moraima Jiménez, Elisa Roldán, Candela Fernández-Naval, Guillermo Villacampa, Mónica Martinez-Gallo, Daniel Medina-Gil, Soraya Peralta-Garzón, Gemma Pujadas, Cristina Hernández, Carlota Pagès, et al.

    Recent studies have shown a suboptimal humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients diagnosed with hematologic malignancies; however, data about cellular immunogenicity are scarce. The aim of this study was to evaluate both the humoral and cellular immunogenicity 1 month after the second dose of the mRNA-1273 vaccine. Antibody titers were measured by using the Elecsys and LIAISON anti–SARS-CoV-2 S assays, and T-cell response was assessed by using interferon-γ release immunoassay technology. Overall, 76.3% (184 of 241) of patients developed humoral immunity, and the cellular response rate was 79% (184 of 233). Hypogammaglobulinemia, lymphopenia, active hematologic treatment, and anti-CD20 therapy during the previous 6 months were associated with an inferior humoral response. Conversely, age >65 years, active disease, lymphopenia, and immunosuppressive treatment of graft-versus-host disease (GVHD) were associated with an impaired cellular response. A significant dissociation between the humoral and cellular responses was observed in patients treated with anti-CD20 therapy (the humoral response was 17.5%, whereas the cellular response was 71.1%). In these patients, B-cell aplasia was confirmed while T-cell counts were preserved. In contrast, humoral response was observed in 77.3% of patients undergoing immunosuppressive treatment of GVHD, whereas only 52.4% had a cellular response. The cellular and humoral responses to the SARS-CoV-2 mRNA-1273 vaccine in patients with hematologic malignancies are highly influenced by the presence of treatments such as anti-CD20 therapy and immunosuppressive agents. This observation has implications for the further management of these patients.


  • Open Access

    Paracrine Met signaling triggers epithelial–mesenchymal transition in mammary luminal progenitors, affecting their fate

    by Amandine Di-Cicco, Valérie Petit, Aurélie Chiche, Laura Bresson, Mathilde Romagnoli, Véronique Orian-Rousseau, Maria Dm Vivanco, Daniel Medina, Marisa M Faraldo, Marina A Glukhova, et al.

    HGF/Met signaling has recently been associated with basal-type breast cancers, which are thought to originate from progenitor cells residing in the luminal compartment of the mammary epithelium. We found that ICAM-1 efficiently marks mammary luminal progenitors comprising hormone receptor-positive and receptor-negative cells, presumably ductal and alveolar progenitors. Both cell populations strongly express Met, while HGF is produced by stromal and basal myoepithelial cells. We show that persistent HGF treatment stimulates the clonogenic activity of ICAM1-positive luminal progenitors, controlling their survival and proliferation, and leads to the expression of basal cell characteristics, including stem cell potential. This is accompanied by the induction of Snai1 and Snai2, two major transcription factors triggering epithelial–mesenchymal transition, the repression of the luminal-regulatory genes Elf5 and Hey1, and claudin down-regulation. Our data strongly indicate that paracrine Met signaling can control the function of luminal progenitors and modulate their fate during mammary development and tumorigenesis.


  • Open Access

    Somatic loss of p53 leads to stem/progenitor cell amplification in both mammary epithelial compartments, basal and luminal

    by Aurélie Chiche, Mejdi Moumen, Valérie Petit, Jos Jonkers, Daniel Medina, Marie-Ange Deugnier, Marisa M. Faraldo, Marina A. Glukhova

    Mammary epithelium comprises a layer of luminal cells and a basal myoepithelial cell layer. Both mammary epithelial compartments, basal and luminal, contain stem and progenitor cells, but only basal cells are capable of gland regeneration upon transplantation. Aberrant expansion of stem/progenitor cell populations is considered to contribute to breast tumorigenesis. Germline deletions of p53 in humans and mice confer a predisposition to tumors, and stem cell frequency is abnormally high in the mammary epithelium of p53-deficient mice. However, it is unknown whether stem/progenitor cell amplification occurs in both, basal and luminal cell populations in p53-deficient mammary tissue. We used a conditional gene deletion approach to study the role of p53 in stem/progenitor cells residing in the mammary luminal and basal layers. Using two- and three-dimensional cell culture assays, we showed that p53 loss led to the expansion of clonogenic stem/progenitor cells in both mammary epithelial cell layers. Moreover, following p53 deletion, luminal and basal stem/progenitor cells acquired a capacity for unlimited propagation in mammosphere culture. Furthermore, limiting dilution and serial transplantation assays revealed amplification and enhanced self-renewal in the basal regenerating cell population of p53-deficient mammary epithelium. Our data suggest that the increase in stem/progenitor cell activity may be, at least, partially mediated by the Notch pathway. Taken together, these results strongly indicate that p53 restricts the propagation and self-renewal of stem/progenitor cells in both layers of the mammary epithelium providing further insight into the impact of p53 loss in breast cancerogenesis. Stem Cells 2013;31:1857-1867


  • A mammary-specific model demonstrates the role of the p53 tumor suppressor gene in tumor development

    by D J Jerry, F S Kittrell, C Kuperwasser, R Laucirica, E S Dickinson, P J Bonilla, J S Butel, D Medina

    Although alterations in the p53 tumor suppressor gene are detected frequently in human breast cancers, mammary tumors are observed infrequently in p53(null) mice. This has led to the suggestion that absence of p53 alone is not sufficient for induction of mammary tumors. However, early death of p53(null) mice from thymic lymphomas may obscure tumor phenotypes that would develop later. Therefore, p53(null) mammary epithelium was transplanted into cleared mammary fat pads of wild type p53 BALB/c hosts to allow long-term analysis of mammary tumor phenotypes. Five treatments were compared for their effects on tumor incidence in hosts bearing transplants of p53(null) and p53wt mammary epithelium. The treatment groups were: (1) untreated; (2) continuous hormone stimulation with pituitary isografts; (3) multiple pregnancies; (4) DMBA alone; and (5) DMBA+pituitary isografts. The tumor incidences in p53(null) vs p53wt mammary transplants for each treatment group were 62% vs 0%, 100% vs 0%, 68% vs 0%, 60% vs 4% and 91% vs 14%, respectively. The mammary tumors that developed in the p53(null) mammary epithelium were all adenocarcinomas and were frequently aneuploid. These data demonstrate that the absence of p53 is sufficient to cause development of mammary tumors and that hormonal stimulation enhances the tumorigenicity of p53(null) mammary epithelium to a greater extent than DMBA exposure alone. This model provides an in situ approach to examine the molecular basis for the role of p53 in the regulation of mammary tumorigenesis.